Amd Age-Related Macular Degeneration

Zimura showed positive results at 18 months in a phase 3 clinical trial in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric bio.

A pharmacokinetic analysis of the LADDER trial indicates that the Port Delivery System filled with the higher 100 mg/mL dose provides continuous release of ranibizumab through at least 16 months.

Several modifications to the insertion procedure for the Port Delivery System helped to reduce the rate of postoperative vitreous hemorrhage in the LADDER trial, according to a speaker.